arcutis.com - יחס שווי שוק לשווי בספרים ARQT

The success of Arcutis Biotherapeutics (ARQT) relies on insurance approvals and the pace of bringing dermatological products to market, which necessitates liquidity control as the company moves toward break-even, with the indicator standing at 17.80. Visualizing the market price helps track the dynamics of this biopharma business, which develops advanced medications for chronic skin pathologies to grow marginal FCF. The company generates revenue from the sale of topical ointments through pharmacies and insurance funds for patients with dermatitis.

This multiple compares the market value of the business with its net assets, revealing the extent to which the market overvalues the company relative to its book value. By analyzing the current market-to-book capitalization ratio, an investor assesses the stability of Arcutis Biotherapeutics (ARQT), where high asset value is supported by an advanced specialized distribution network for dermatological products that minimizes supply chain disruption risks and sustains margins.